Atherogenic risk in rheumatoid arthritis patients. Classification beginning with immunoinflamatory response variables

Authors

  • Ulises Mendoza Coussette Hospital Comandante Faustino Pérez. Ciudad de Matanzas
  • María Eugenia Alonso Biosca Facultad de Biología. Universidad de La Habana. La Habana, Cuba

Keywords:

rheumatoid arthritis, coronary risk, atherogenic index, rheumatoid factor

Abstract

The early coronary risk’s classification in rheumatoid arthritis patients is a necessity during approach them, yet. To evaluate the discriminatory capacity between coronary risk’s categories of the rheumatoid factor, c reactive protein, complement C3, complement C4 and 28 joint count Disease Activity Score variables carried out an observational analytic cross sectional study in a Matanzas rheumatoid arthritis patients group. The coronary risk’s categories was defined as minor and major according lipoprotein(a), apolipoprotein B/ apolipoprotein A1, LDL/HDL cholesterol, apolipoprotein B/LDL cholesterol and atherogenic ratio’s values within or without of reference rank, respectively. The 18.0 version statistic software SPSS was used for discriminatory analysis. The DAS28, complement C3 and C reactive protein defined discriminatory functions between the coronary risk categories according to the LDL/HDL cholesterol, apolipoprotein B/ apolipoprotein A1 and apolipoprotein B/LDL cholesterol, respectively [F > 3.84; Wilks’s Lambda, p < 0.05]. In every set the discriminatory function showed more than 50 % of global right classification of patients analized. Cut off in 5,75; 7.35 mg/L, and 1.13 Gr/L for 28 joint count Disease Activity Score, C reactive protein, and complement C3, respectively, showed suitable discriminatory capacity [area under curve > 0.5 (p < 0.05); positive probable ratio ≥ 1.5]. The results showed possibility of stratifying directly coronary risk linked lipoprotein metabolism beginning with DAS28, C reactive protein, and complement C3 in rheumatoid arthritis patients.

Downloads

Download data is not yet available.

Author Biographies

Ulises Mendoza Coussette, Hospital Comandante Faustino Pérez. Ciudad de Matanzas

Departamento de Laboratorio Clínico.

Médico especialista de 1er Grado en Bioquímica Clínica, MSc. de Laboratorio clínico, profesor asistente, coordinador de ensayos clínicos de la institución.

María Eugenia Alonso Biosca, Facultad de Biología. Universidad de La Habana. La Habana, Cuba

Dra. C. Licenciada en Biología

References

Ráček V, Němec P. Rheumatoid Arthritis – an independent risk factor for cardiovascular disease. Vnitr Lek. 2012;58(11):834-8.

Gkaliagkousi E, Gavriilaki E, Doumas M, Pedtidis K, Aslanidis S, Stella D. Cardiovascular risk in rheumatoid arthritis: pathogenesis, diagnosis, and management. Journal Clinical Rheumatology. 2012;18(8):422-30.

Montecucco F, Mach F. Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis. Rheumatology. 2009; 48(1):11-22.

Gómez A. Nuevos criterios de clasificación de artritis reumatoide. Reumatol C lin. 2011;6 Suppl. 3:S33-S7.

Kokuina E, Chico A, Carballar L, Gutiérrez A, Soto J, Estévez M et al. Factor reumatoide: asociación con la erosión radiológica y actividad de la artritis reumatoide. Rev cubana med [Internet]. 2008 Sep [citado 2014 Ago 2];43(3). Disponible en URL: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S003475232008000300004&lng=es

Maneiro RJ, Salgado E, Carmona L, Gómez JJ. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis. Semin Arthritis Rheum. 2013;43(1):9-17.

Mendoza U, Rodríguez JA, Alonso MA. Marcadores de respuesta inflamatoria y riesgo coronario en pacientes con Artritis Reumatoide. Revista cubana de investigaciones biomédicas [Internet] 2013 [citado: 2014 ago 2];32(3). Disponible en: http://bvs.sld.cu/revistas/ibi/vol32_3_13/ibi09313.htm

Wallach J. Enfermedades cardiovasculares. Interpretación clínica de las pruebas de laboratorio. La Habana: Ed. Ciencias Médicas; 2006: p. 141-67.

Análisis discriminante: El procedimiento discriminante. En: SPSS Guía para el análisis de datos. Madrid: Ed. Hispanoportuguesa; 2007. p. 772-855.

Walldius G, Jungner I. The ApoB/apoA1 ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy- a review of the evidence. Journal of Internal Medicine. 2006;259:493-519.

Hurt E, Paredes S, Masana L, Camejo G, Sartipy P, Rosengren B et al. Elevated levels of small, low-Density Lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis. Possible contribution of phospholipase A2 to this atherogenic profile. Arthritis & Rheumatism. 2001;44(12):2761-7

Published

2014-12-29

How to Cite

1.
Mendoza Coussette U, Alonso Biosca ME. Atherogenic risk in rheumatoid arthritis patients. Classification beginning with immunoinflamatory response variables. Rev. cuba. de Reumatol. [Internet]. 2014 Dec. 29 [cited 2025 Mar. 14];17(1):25-31. Available from: https://revreumatologia.sld.cu/index.php/reumatologia/article/view/382

Issue

Section

Original research article